2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC—A Closer Look at the Paradigm-Shifting Synergy of Safety, Efficacy, and Equitable Access

This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.

• Review top-line data presented at ASCO 2022 focused on the evolving—and expanding—placement of targeted therapies in the management of metastatic EGFR+ NSCLC.
• Evaluate these data in context of the established EGFR+ treatment calculus, and identify pivotal facets or key scientific messages from ASCO 2022 that possess the potential to change practice.
• Using patient-centric viewpoints, discuss the burden of financial toxicity as an access obstacle to oral oncolytic therapeutics, with an emphasis on equitable access to EGFR-targeted tyrosine kinase inhibitors (TKIs).

Supported through an independent educational grant from EQRx International, Inc.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:
Helena Yu, MD–has disclosed that she is an advisor or consultant to AstraZeneca, Black Diamond, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, and Janssen. Her institution receives research support from AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Erasca, Janssen, Novartis, and Pfizer.
Jill Feldman, MA–has disclosed that she is an advisor or consultant to Daiichi Sankyo, EQRx, and Janssen and receives speaking honoraria from AstraZeneca, Blueprint Medicines, and Takeda.
Lisa Shotyk, RN, MSN, APN-BC–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty:
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO–has disclosed that she receives grants from Amgen, AstraZeneca, Bayer, EMD Serono, Guardant Health, Novartis, Pfizer, Roche, and. She receives research support from Bristol-Myers Squibb, Guardant Health, Inivata, Lilly, and Merck Sharp & Dohme. Dr. Leighl was an advisor/consultant for Beigene, GlaxoSmithKline, and Puma Biotechnology. She also receives other financial or material support from Amgen, Bristol-Myers Squibb, Genzyme, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and Takeda.

Peer Reviewers:
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:
Joan B. Fowler, PharmD, BCPP–has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Rebecca Weaver, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.